Literature DB >> 2993421

Alteration in antibody reactivity with foot-and-mouth disease virus (FMDV) 146S antigen before and after binding to a solid phase or complexing with specific antibody.

K C McCullough, J R Crowther, R N Butcher.   

Abstract

This paper describes the reactions of a number of monoclonal antibodies produced against purified whole virions of foot-and-mouth disease virus in 3 different enzyme immunoassay systems. The first system used whole virus bound non-covalently to microplates; the second used whole virus trapped by a polyclonal antibody which was bound to microplates; and the third allowed the monoclonal antibodies to react with the whole virions in suspension (liquid phase) before trapping by the solid-phase-bound polyclonal antibody. Different reactions with panels of monoclonal antibodies were observed depending on which system was used. Such variations in reactivity give an insight into the alterations in the expression of virus epitopes in the different enzyme immunoassay systems. The reactions of selected monoclonal antibodies were used to illustrate these changes and the results compared to those obtained in similar systems using polyclonal antisera produced against isolated virion polypeptides.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993421     DOI: 10.1016/0022-1759(85)90228-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  Characterization of monoclonal antibodies against a type SAT 2 foot-and-mouth disease virus.

Authors:  J R Crowther; C A Rowe; R Butcher
Journal:  Epidemiol Infect       Date:  1993-10       Impact factor: 2.451

2.  Limitations of different ELISA procedures for localizing epitopes in viral coat protein subunits.

Authors:  E L Dekker; C Porta; M H Van Regenmortel
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 3.  Monoclonal antibodies: implications for virology. Brief review.

Authors:  K C McCullough
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

4.  Immune protection against foot-and-mouth disease virus studied using virus-neutralizing and non-neutralizing concentrations of monoclonal antibodies.

Authors:  K C McCullough; J R Crowther; R N Butcher; W C Carpenter; E Brocchi; L Capucci; F De Simone
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

5.  A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles.

Authors:  N R Parry; A Syred; D J Rowlands; F Brown
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

6.  Chimeric polioviruses that include sequences derived from two independent antigenic sites of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies against FMDV in guinea pigs.

Authors:  J D Kitson; K L Burke; L A Pullen; G J Belsham; J W Almond
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  Vaccinia virus expression of the VP7 protein of South African bluetongue virus serotype 4 and its use as an antigen in a capture ELISA.

Authors:  M Cloete; D H du Plessis; A A van Dijk; H Huismans; G J Viljoen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  Some observations on the binding properties of alfalfa mosaic virus to polystyrene and its significance to indirect ELISA.

Authors:  M R Hajimorad; R I Francki
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

9.  Conformational specificity of monoclonal antibodies used in the diagnosis of tomato mosaic virus.

Authors:  E L Dekker; I Dore; C Porta; M H van Regenmortel
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

10.  Isolation of Single-Domain Antibody Fragments That Preferentially Detect Intact (146S) Particles of Foot-and-Mouth Disease Virus for Use in Vaccine Quality Control.

Authors:  Michiel M Harmsen; Julian Seago; Eva Perez; Bryan Charleston; Phaedra L Eblé; Aldo Dekker
Journal:  Front Immunol       Date:  2017-08-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.